The financials
Xeris Biopharma Holdings, Inc. by the numbers
Xeris Biopharma Holdings, Inc. (XERS) reported revenue of $83M in Q1 2026 (quarter ended March 31, 2026), up 38% from the same quarter a year earlier. That came with a gross margin of 87% and net income of $2.2M (2.7% of revenue). For the full year FY2025, revenue was $292M (+44% year on year) and net income $554K. Its largest product in 2026-Q1 was Recorlev at $50M, 60% of the disclosed total, just ahead of Gvoke at 25%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $83M | $60M | +38% |
| Gross profit | $73M | $51M | +41% |
| Operating income | $7.9M | −$3.1M | to a profit |
| Net income | $2.2M | −$9.2M | to a profit |
| Diluted EPS | $0.01 | −$0.06 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Recorlev | $50M | 60% |
| Gvoke | $21M | 25% |
| Keveyis | $12M | 14% |
| Royalty Contract And Other | $673K | 0.8% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $83.1M (+12%)
Recorlev grew +95% year on yearRoyalty Contract And Other -71% year on year
Segment Latestquarter on quarteryear on year
- Recorlev$49.8M$49.8MQoQ +35%year on year +95%+35%+95%
- Gvoke$20.8M$20.8MQoQ -17%year on year -0.22%-17%-0.22%
- Keveyis$11.9M$11.9MQoQ -0.43%year on year +4.0%-0.43%+4.0%
- Royalty Contract And Other$673.0K$673.0KQoQ +112%year on year -71%+112%-71%
- Product Other--QoQ -year on year ---
Drug Manufacturers - Specialty & Generic
Ranks #12 of 28 by Smart Score